Department of Minimal-Invasive Intervention, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou 450008, China.
Department of Medical Gastroenterology, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou 450008, China.
Korean J Radiol. 2018 Mar-Apr;19(2):237-246. doi: 10.3348/kjr.2018.19.2.237. Epub 2018 Feb 22.
To evaluate the efficacy and prognostic factors associated with transcatheter arterial chemoembolization (TACE) combined with microwave ablation (MWA) versus TACE alone for a large solitary or multinodular hepatocellular carcinomas (HCCs).
This retrospective study involved 258 patients with a large solitary or multinodular HCCs (not more than 10 tumors) who underwent TACE + MWA (n = 92) or TACE alone (n = 166) between July 2011 and April 2015. Local tumor control, survival outcomes, and complications were compared between the two groups. Prognostic factors for time to progression (TTP) and overall survival (OS) were evaluated by univariate and multivariate analyses.
The median duration of follow-up was 21.2 months (range, 4-45 months). The median TTP and OS were 12.5 months and 26.6 months, respectively, for the TACE + MWA group and 6.7 months and 17.1 months, respectively, for the TACE group ( < 0.001). The 1-, 2-, and 3-year OS rates were 85.9, 59.8, and 32.6%, respectively, for the TACE + MWA group and 59.0, 40.4, and 11.4%, respectively, for the TACE group ( < 0.001). The corresponding recurrence rates were 47.8, 78.3, and 94.6% for the TACE + MWA group, respectively, and 74.7, 96.4, and 97.6%, respectively, for the TACE group ( < 0.001). Logistic regression analyses showed that the treatment method, tumor size, and tumor number were significant prognostic factors for TTP and OS.
TACE + MWA appears to have more advantages compared to TACE in prolonging OS, with a satisfactory TTP, for inpatients with solitary large or multinodular HCCs. Treatment method, tumor size, and tumor number are significant prognostic factors for TTP and OS. Further randomized, multi-center, prospective trials are required to confirm the findings of this study.
评估经导管动脉化疗栓塞(TACE)联合微波消融(MWA)与单纯 TACE 治疗大的单发或多结节肝细胞癌(HCC)的疗效和相关预后因素。
本回顾性研究纳入了 2011 年 7 月至 2015 年 4 月期间接受 TACE+MWA(n=92)或单纯 TACE(n=166)治疗的 258 例大的单发或多结节 HCC(不超过 10 个肿瘤)患者。比较两组的局部肿瘤控制、生存结局和并发症。通过单因素和多因素分析评估无进展生存期(TTP)和总生存期(OS)的预后因素。
中位随访时间为 21.2 个月(范围:4-45 个月)。TACE+MWA 组的中位 TTP 和 OS 分别为 12.5 个月和 26.6 个月,TACE 组分别为 6.7 个月和 17.1 个月(<0.001)。TACE+MWA 组的 1、2 和 3 年 OS 率分别为 85.9%、59.8%和 32.6%,TACE 组分别为 59.0%、40.4%和 11.4%(<0.001)。TACE+MWA 组的相应复发率分别为 47.8%、78.3%和 94.6%,TACE 组分别为 74.7%、96.4%和 97.6%(<0.001)。Logistic 回归分析表明,治疗方法、肿瘤大小和肿瘤数量是 TTP 和 OS 的显著预后因素。
与单纯 TACE 相比,TACE+MWA 似乎在延长 OS 方面具有更多优势,同时具有令人满意的 TTP,适用于单发大或多结节 HCC 住院患者。治疗方法、肿瘤大小和肿瘤数量是 TTP 和 OS 的显著预后因素。需要进一步的随机、多中心、前瞻性试验来证实本研究的结果。